LaFleur & Godfrey LLC Has $21.57 Million Stock Position in Johnson & Johnson (NYSE:JNJ)

LaFleur & Godfrey LLC decreased its holdings in Johnson & Johnson (NYSE:JNJGet Rating) by 10.6% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 121,726 shares of the company’s stock after selling 14,362 shares during the quarter. Johnson & Johnson accounts for approximately 2.9% of LaFleur & Godfrey LLC’s holdings, making the stock its 6th largest position. LaFleur & Godfrey LLC’s holdings in Johnson & Johnson were worth $21,574,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of JNJ. Magnolia Capital Management Ltd. lifted its stake in Johnson & Johnson by 0.5% in the 1st quarter. Magnolia Capital Management Ltd. now owns 11,162 shares of the company’s stock worth $1,978,000 after acquiring an additional 55 shares in the last quarter. Howard Financial Services LTD. lifted its stake in Johnson & Johnson by 2.1% in the 1st quarter. Howard Financial Services LTD. now owns 2,757 shares of the company’s stock worth $489,000 after acquiring an additional 57 shares in the last quarter. American Financial Advisors LLC lifted its stake in Johnson & Johnson by 2.1% in the 1st quarter. American Financial Advisors LLC now owns 2,715 shares of the company’s stock worth $481,000 after acquiring an additional 57 shares in the last quarter. Capital Investment Counsel Inc lifted its stake in Johnson & Johnson by 0.8% in the 4th quarter. Capital Investment Counsel Inc now owns 7,796 shares of the company’s stock worth $1,334,000 after acquiring an additional 59 shares in the last quarter. Finally, Kwmg LLC lifted its stake in Johnson & Johnson by 2.6% in the 1st quarter. Kwmg LLC now owns 2,354 shares of the company’s stock worth $417,000 after acquiring an additional 59 shares in the last quarter. Institutional investors own 68.78% of the company’s stock.

Johnson & Johnson Stock Performance

Shares of NYSE JNJ opened at $174.52 on Monday. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.14 and a current ratio of 1.39. The firm has a market cap of $459.23 billion, a price-to-earnings ratio of 25.40, a P/E/G ratio of 3.28 and a beta of 0.63. The business’s 50-day simple moving average is $175.95 and its 200-day simple moving average is $174.46. Johnson & Johnson has a 52 week low of $155.72 and a 52 week high of $186.69.

Johnson & Johnson (NYSE:JNJGet Rating) last released its earnings results on Tuesday, July 19th. The company reported $2.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.57 by $0.02. The firm had revenue of $24.02 billion for the quarter, compared to analyst estimates of $23.85 billion. Johnson & Johnson had a return on equity of 36.56% and a net margin of 19.21%. The company’s revenue was up 3.0% on a year-over-year basis. During the same quarter last year, the firm posted $2.48 EPS. As a group, equities research analysts expect that Johnson & Johnson will post 10.05 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 6th. Shareholders of record on Tuesday, August 23rd will be issued a $1.13 dividend. This represents a $4.52 dividend on an annualized basis and a yield of 2.59%. The ex-dividend date is Monday, August 22nd. Johnson & Johnson’s dividend payout ratio (DPR) is currently 65.79%.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 40,000 shares of the firm’s stock in a transaction that occurred on Friday, June 10th. The stock was sold at an average price of $173.00, for a total value of $6,920,000.00. Following the sale, the executive vice president now owns 71,311 shares of the company’s stock, valued at approximately $12,336,803. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 40,000 shares of the firm’s stock in a transaction that occurred on Friday, June 10th. The stock was sold at an average price of $173.00, for a total value of $6,920,000.00. Following the completion of the sale, the executive vice president now owns 71,311 shares in the company, valued at approximately $12,336,803. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CAO Robert J. Decker sold 8,462 shares of the firm’s stock in a transaction that occurred on Thursday, May 26th. The stock was sold at an average price of $180.00, for a total value of $1,523,160.00. Following the completion of the sale, the chief accounting officer now owns 15,473 shares of the company’s stock, valued at approximately $2,785,140. The disclosure for this sale can be found here. Insiders own 0.35% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have weighed in on the company. Raymond James upped their target price on Johnson & Johnson from $195.00 to $196.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 20th. Citigroup dropped their target price on Johnson & Johnson from $205.00 to $201.00 in a research report on Wednesday, July 20th. UBS Group dropped their target price on Johnson & Johnson from $185.00 to $180.00 in a research report on Thursday, July 21st. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, May 17th. Finally, The Goldman Sachs Group upped their target price on Johnson & Johnson from $163.00 to $181.00 and gave the stock a “neutral” rating in a research report on Tuesday, April 12th. Four investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Johnson & Johnson currently has an average rating of “Moderate Buy” and a consensus price target of $189.89.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Articles

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.